Of 29 infants with acute myeloid leukemia (AML), 14 (48%) had various 11q23 translocations. MLL rearrangements were examined in 21 of the 29 patients, and 11 (52%) showed the rearrangements. 11q23 translocations and/or MLL rearrangements were found in 17 (58%) of the 29 patients. While all but one of the 17 patients with 11q23/MLL rearrangements had M4 or M5 type of the FAB classification, the 12 patients without such rearrangements had various FAB types, including M2, M4, M4EO, M6 and M7. Of the 12 patients with other chromosome abnormalities or normal karyotypes, two had inv(16) or t(16;16), one had t(1;22)(p13;q13), and two had a novel translocation, t(7;12)(q32;p13). The breakpoint on 12p of the t(7;12) was assigned to intron 1 or the region just upstream of exon 1 of the TEL/ETV6 gene by fluorescence in situ hybridization. The event-free survival at 5 years for the 17 patients with 11q23/MLL rearrangements was 42.2%, and that for the 12 patients without such rearrangements was 31.3% (P = 0.5544). 11q23/MLL rearrangements have been frequently reported and a poor prognosis in infant acute lymphoblastic leukemia implied. Our study showed that while 11q23/MLL rearrangements were also common in infant AML, AML infants with such rearrangements had a clinical outcome similar to that of AML infants without such rearrangements.
Introduction
Infant acute leukemia is frequently accompanied by 11q23 translocations, 1 which form fusion genes between MLL in 11q23 and AF4 in 4q21, ENL in 19p13.3, or other genes in various chromosomal regions. 2, 3 Several investigators have reported that 11q23/MLL rearrangements are frequent (70-80%) in infant acute lymphoblastic leukemia (ALL), and unequivocally predict a poor clinical outcome. [4] [5] [6] [7] [8] Acute myeloid leukemia (AML) is less common than ALL in infants, and only two series of infant AML have previously evaluated frequency and prognostic implication of 11q23/MLL rearrangements. 7, 9 Recurrent chromosome translocations other than 11q23 translocations in infant AML include t(1;22)(p13;q13) and t(8;16)(p11;p13), which are associated with AML, M7 and AML, M4/M5, respectively. 10, 11 No other recurrent translocations have formerly been identified in infant AML.
We studied chromosomes and/or MLL rearrangements in 29 infants with AML. We found 11q23/MLL rearrangements in 58% of the infants, and found that the infants with 11q23/MLL rearrangements had a clinical outcome similar to that of AML Correspondence: Y Kaneko, Department of Cancer Chemotherapy, Saitama Cancer Center Hospital, Ina, Saitama, 362-0806 Japan; Fax (+81) 48 723-5197 Received 24 November 1998; accepted 9 March 1999 infants without such rearrangements. We also found that certain chromosome translocations other than 11q23 translocations were recurrently seen in infant AML.
Materials and methods

Patient samples
Bone marrow (BM) or peripheral blood (PB) was obtained from 30 infants (15 males and 15 females) under 12 months of age (the median age, 6 months) who were hospitalized in 18 institutions throughout Japan between February 1986 and May 1998. Down's syndrome infants with leukemia were excluded from the study. AML was diagnosed on the basis of the FAB classification. 12 Patients were treated according to the CCLSG infant leukemia protocol, 13 the TCCSG AML protocol, 14 or the ANLL-91 protocol. 15 
Chromosome studies
Chromosomes from BM or PB cells were studied by the methods described. 1, 16 Chromosome abnormalities were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 1995. 17 Karyotypes of five patients (Nos 276, 306, 354, 380 and 596) have been published elsewhere. 1 
Southern blot analysis
DNA was extracted from bone marrow or peripheral blood cells, digested with BamHI or HindIII, electrophoresed in 0.7% agarose gels, and transferred on to nylon membranes (Hybond N+; Amersham, Bucks, UK). Hybridization was performed with an MLL cDNA probe, probe X, which covered the breakpoint cluster region (exon 5-11) of MLL. 18 
Fluorescence in situ hybridization analysis (FISH)
Two-color FISH with cosmids derived from the TEL/ETV6 gene was performed on leukemic metaphase cells from two patients as described previously. 19 A cosmid clone, 179A6, covering exon 1 of TEL was labeled with biotin (bio)-16-UTP, and a cosmid clone, 50F4, covering exon 2 was labeled with digoxigenin (dig)-11-dUTP (Boehringer Mannheim, Mannheim, Germany). 20 The cosmid clones were kindly provided by Dr P Marynen, Center for Human Genetics, Campus Gasthuisberg, Leuven, Belgium.
Statistical analysis
Significance of differences in various biological and clinical aspects of the disease among the patient groups was examined by the 2 or Fisher's exact test. Overall and event-free survivals for each group of patients were estimated on 9 November 1998, by the Kaplan-Meier method, 21 and were compared using the log-rank test. 22 Time to failure was defined as the interval between remission induction and relapse or death from any cause. Failure to achieve complete remission was considered an event of day 1.
Results
Chromosomes of the BM or PB cells were successfully studied from 29 of the 30 patients. Samples for cytogenetic studies were obtained before therapy from 27 patients and at relapse from two patients (Nos 596 and 1979). Karyotypes are shown in Table 1 . Clonal chromosome abnormalities were found in (Tables 1 and 2) . Two-color FISH was performed on the leukemic metaphase cells with t(7;12)(q32;p13) of patients 1824 and 1901. In the cells of patient 1824, cosmid 179A6, covering exon 1 of TEL, hybridized to the der(7) chromosome and normal chromosome 12, and cosmid 50F4, covering exon 2 of TEL, hybridized to the der(12) chromosome and normal chromosome 12. These results indicated that the breakpoint on 12p Arrowheads indicate the breakpoints of t(7;12)(q32;p13). While the 7;12 translocations in (c) and (d) were reciprocal, the deletion, del(12)(p13), appears to have occurred after the reciprocal translocation, t(7;12)(q32;p13), in (a) and (b).
was located in intron 1 of TEL. In the cells of patient 1901, cosmid 179A6 hybridized to both the der(7) and der(12) chromosomes as well as normal chromosome 12, and 50F4 hybridized to the der(12) chromosome and normal chromosome 12. These results indicated that the breakpoint was located in intron 1 or the region just upstream of exon 1 of TEL.
The relationship between chromosome changes and the MLL status is summarized in Table 2 . Of nine patients with 11q23 translocations who were examined by Southern blotting, eight had rearranged MLL and one with t(10;11)(p15;q23) had germline MLL. Of eight patients with chromosome abnormalities other than 11q23 translocations, one with t(6;19)(q25;p13) had rearranged MLL and seven had germline MLL. Of four patients with a normal karyotype, two had germline MLL and two had rearranged MLL. Unfortu- The 12 patients enclosed by a rectangle belong to group B, and the other 17 patients outside the rectangle belong to group A.
nately, cytogenetic samples were not available for two patients with t(10;11)(p15;q23) or t(6;19)(q25;p13) and for two patients with a normal karyotype and rearranged MLL. The 29 patients were classified into two groups; group A consisted of 17 patients with rearranged MLL or 11q23 translocations, and group B consisted of 12 patients with germline MLL or chromosome changes other than the 11q23 translocation (Tables 1 and 2 ). Patient 1242, with the 11q23 translocation and germline MLL, is included in group A, because Southern blot analysis with a single MLL cDNA probe cannot detect rare 11q23 translocation breakpoints which are located outside the breakpoint cluster region of MLL. 5 Three patients (Nos 306, 380 and 1901) with chromosome changes other than 11q23 translocations and no data on the MLL status were included in group B, because these patients had AML-M2 with 5q−, AML-M4 with t (8;22) , or AML-M2 with t(7;11), ie chromosome changes unlikely for infant AML with MLL rearrangements. There were no significant differences in age, sex, white blood cell counts, lactate dehydrogenase values, or complete remission rate between the two groups. While all of the 17 patients but one in group A were classified as M4 or M5 type, only three of the 12 patients in group B were classified as M4 or M5 type (P = 0.001).
Event-free survival (EFS) at 5 years was 42.2% (95% confidence interval (CI), 17.2-67.2) for group A patients, and 31.3% (95% CI, 3.9-58.6) for group B patients (P = 0.5544). Overall survival (95% CI) at 5 years was 40.0% (14.5-65.5) for group A patients, and 37.5% (−11.3-48.8) for group B patients (P = 0.4939). EFS (95% CI) at 5 years was 47.7% (15.1-80.3) for 11 patients with rearranged MLL, and 26.7% (−2.7-56.1) for 10 patients with germline MLL (P = 0.3328). Overall survival (95% CI) at 5 years was 46.8% (14.0-79.5) for 11 patients with rearranged MLL, and 36.0 (4.4-67.6) for 10 patients with germline MLL (P = 0.5659).
Discussion
In chromosome and Southern blotting analyses of 29 AML infants, we found 11q23/MLL rearrangements in 17 (58%) of them. Pui et al 7 reported 11q23 translocations in nine (36%) of 25 infants with AML by cytogenetic analysis, and Hilden et al 9 reported MLL rearrangements in 29 (66%) of 44 infants with AML by Southern blotting analysis. In addition, MartinezCliment et al 23 reported MLL rearrangements in six (50%) of 12 infants with AML by FISH and/or Southern blotting analysis; one of the six patients was found to have t(11;19)(q23;p13.1) by FISH in the leukemic cells, which had previously been identified to have a normal karyotype. Our data on infant AML and the data previously reported in infant ALL and AML showed that some infant leukemias with a normal karyotype or chromosome abnormalities other than 11q23 translocations had MLL rearrangements (Tables 1 and 2 ). These findings may explain the higher incidence of the 11q23/MLL rearrangements in the present series and the series of infant AML reported by Hilden et al 9 or Martinez-Climent et al 23 than in that reported by Pui et al. 7 The great majority of AML infants with 11q23/MLL rearrangements in the present series had M4 or M5 type, and a similar association has been reported in adult as well as infant AML with 11q23/MLL rearrangements. 24, 25 While t(4;11)(q21;q23) or t(11;19)(q23;p13.3) predominated in infant ALL with 11q23/MLL rearrangements, [4] [5] [6] 8 none of the 11q23 translocations reported for the present series or the previously reported series seemed to predominate in infant and adult AML with 11q23/MLL rearrangements. 24, 25 Among various 11q23 translocations found in infant AML, t(11;19)(q23;p13.1) was relatively common. The association of t(11;19)(q23;p13.1) with leukemia of a myeloid lineage has been reported previously. 26 The present data showed that AML infants with 11q23/MLL rearrangements had 42% EFS at 5 years, which did not significantly differ from the outcome of AML infants without such rearrangements. Pui et al 7 and Hilden et al 9 reported data showing no significant differences in EFS between AML infants with 11q23/MLL rearrangements and those without them, although Hilden et al 9 showed a trend towards a worse outcome in infants with MLL rearrangements. Children with t(9;11)(p22;q23)-associated AML were reported to have a favorable prognosis. [27] [28] [29] Adults with t(9;11)(p22;q23)-associated AML had a better treatment outcome than adults with other 11q23 translocation-associated AML. 30 The partner gene, AF9, 31 which juxtaposes to MLL, may influence the favorable prognosis of patients with t(9;11) AML. Because t(9;11)(p22;q23) is infrequent in infant AML, the clinical outcome of infants with t(9;11) AML is presently unknown, and the overall prognosis of AML infants with various 11q23/MLL rearrangements may be minimally influenced by the outcome of AML infants with t(9;11). The great majority of ALL infants with 11q23/MLL rearrangements had either t(4;11)q21;q23) or t(11;19)(q23;p13.3), [4] [5] [6] 8 therefore, poor clinical outcomes of ALL infants with MLL rearrangements may have been greatly influenced by the partner genes, AF4 and ENL, which juxtapose to MLL. 2, 3 More infants with 11q23 translocation-associated AML with known clinical outcomes are needed to determine whether specific 11q23 translocations are associated with a favorable or an unfavorable outcome in infant AML.
Of the 12 infants with germline MLL or chromosome changes other than the 11q23 translocation, two had inv (16) or t(16;16), one had t(1;22)(p13;q13), and two had t(7;12)(q32;p13). t(8;21), t(15;17) and inv (16) are the most common chromosome translocations in AML children as well as AML adults. 32 Although t(8;21) and t(15;17) have never been reported in AML infants, 32 inv(16) was previously reported in three of 18 infants with AML. 33 The association of t(1;22) with infant AML-M7 is well known.
10 t(7;12)(q36;p13) was reported in a 1-year-old infant with AML, and FISH on this patient disclosed that the breakpoint on 12p was located in intron 1 of the TEL gene. 20 t(7;12)(q31;p12) was reported in a 1-month-old infant with AML-M5. 34 Although the breakpoints of these 7;12 translocations were differently described, the assignment of breakpoints in the TEL gene in three of the four reported patients, and the tiny chromosome segment of 7q31-7q36, where the exact assignment of the breakpoints is difficult, suggest that all four patients may have had the same translocation, and that t(7;12)(q32;p13) may be specifically associated with infant AML (Figure 1) . The association of 11q23 translocations, inv(16), t(1;22), t(8;16) and t(7;12) with infant leukemia suggests that genes involved in these translocations may be activated in the fetal period or early period of infancy. Future studies will clarify the reason for the association.
